Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 65.56% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 5.87% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -389.31% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -11.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 105.98% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2,385.12% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -15.37% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -1,944,998.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,944,998.80% |
| Dec 31, 2025 | 1,003.53% |
| Sep 30, 2025 | 190.49% |
| Jun 30, 2025 | 139.53% |
| Mar 31, 2025 | 100.09% |
| Dec 31, 2024 | 59.64% |
| Sep 30, 2024 | 64.42% |
| Jun 30, 2024 | 84.59% |
| Mar 31, 2024 | 39.32% |
| Dec 31, 2023 | 16.54% |
| Sep 30, 2023 | 16.54% |
| Jun 30, 2023 | -25.60% |
| Mar 31, 2023 | 29.50% |
| Dec 31, 2022 | -287.69% |
| Sep 30, 2022 | 30.44% |
| Jun 30, 2022 | -30.76% |
| Mar 31, 2022 | 99.63% |
| Dec 31, 2021 | 75.20% |
| Sep 30, 2021 | 88.22% |
| Jun 30, 2021 | 99.99% |